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Abstract
Purpose The relationship between body mass index (BMI) and prostate cancer remains unclear. However, there is an inverse 
association between BMI and prostate-specific antigen (PSA), used for prostate cancer screening. We conducted this review 
to estimate the associations between BMI and (1) prostate cancer, (2) advanced prostate cancer, and (3) PSA.
Methods We searched PubMed and Embase for studies until 02 October 2017 and obtained individual participant data 
from four studies. In total, 78 studies were identified for the association between BMI and prostate cancer, 21 for BMI and 
advanced prostate cancer, and 35 for BMI and PSA. We performed random-effects meta-analysis of linear associations of 
log-PSA and prostate cancer with BMI and, to examine potential non-linearity, of associations between categories of BMI 
and each outcome.
Results In the meta-analyses with continuous BMI, a 5 kg/m2 increase in BMI was associated with a percentage change 
in PSA of − 5.88% (95% CI − 6.87 to − 4.87). Using BMI categories, compared to normal weight men the PSA levels of 
overweight men were 3.43% lower (95% CI − 5.57 to − 1.23), and obese men were 12.9% lower (95% CI − 15.2 to − 10.7). 
Prostate cancer and advanced prostate cancer analyses showed little or no evidence associations.
Conclusion There is little or no evidence of an association between BMI and risk of prostate cancer or advanced prostate 
cancer, and strong evidence of an inverse and non-linear association between BMI and PSA. The association between BMI 
and prostate cancer is likely biased if missed diagnoses are not considered.
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Background
Prostate cancer is the second commonest male cancer 
worldwide, [1] and the most commonly diagnosed cancer 
in men in the UK, with an estimated 47,151 diagnoses in 
2015 [2]. Generally, most prostate cancers are slow grow-
ing, but can metastasize to the bones, lungs, and brain. 
Worldwide, there were an estimated 307,000 deaths from 
prostate cancer in 2012 [1], and in the UK, around 11,600 
men died from prostate cancer in 2016 [2].
Body mass index (BMI) has been associated with 
many cancers [3], but its association with prostate can-
cer is unclear. Previous meta-analyses and reviews have 
suggested that BMI is not associated with prostate cancer 
[4, 5], positively associated with prostate cancer [6, 7], 
inversely associated with localized prostate cancer [8], and 
positively associated with advanced [8], aggressive [9], 
high-grade, and fatal prostate cancers [4]. These meta-
analyses were either limited to cohort studies [4, 5, 7, 8] or 
in need of updating [6, 7]. Additionally, no meta-analysis 
assessed potential non-linear associations between BMI 
and risk of prostate cancer or advanced prostate cancer. 
We therefore sought to perform an updated review of the 
literature, including more studies, and additionally exam-
ining non-linear associations.
BMI has also been inversely associated with prostate-
specific antigen (PSA) [10], although no previous meta-
analysis of this relationship exists. The presence of such an 
association could bias observed relationships between BMI 
and prostate cancer as PSA testing often plays a key role in 
diagnosis. More specifically, a negative association between 
BMI and PSA could lead to a spurious negative association 
or mask a positive association between BMI and localized 
prostate cancer, as obese men, with lower PSA values, would 
be less likely to be offered a biopsy as the result of a PSA 
test. A negative association between BMI and PSA could 
also induce a spurious positive association between BMI 
and advanced prostate cancer, as obese men may be diag-
nosed later, due to their lower PSA levels. In addition, if the 
association between BMI and prostate cancer (or advanced 
prostate cancer) is non-linear, then studies with different 
distributions of BMI will give rise to different estimates 
of the BMI-prostate cancer association. There may also be 
an association between BMI and prostate cancer screening 
behavior (including uptake of PSA testing), though stud-
ies have shown conflicting results. In the USA, men with 
high BMI values were more likely to receive PSA tests [11], 
whereas in the UK men with both very low and high BMI 
values were less likely to receive a PSA test [12]. This fur-
ther complicates the relationship between BMI and prostate 
cancer diagnosis (though not BMI and PSA values), and this 
review does not aim to assess this association.
We systematically reviewed the literature for all relevant 
studies and performed meta-analyses. We also examined 
these relationships using individual participant data (IPD) 
from prostate cancer studies. In analyzing the IPD studies, 
we aimed to account for incomplete and PSA-dependent 
diagnosis by imputing prostate cancer status for all men who 
did not receive a biopsy, and in doing, avoid potential bias 
resulting from an association between BMI and PSA.
Our objectives were to i) precisely quantify the (assumed 
linear) associations between BMI and prostate cancer, 
advanced prostate cancer, and PSA; ii) update previ-
ous meta-analyses using all relevant evidence, including 
case–control studies; and iii) explore potential non-linear-
ity in these associations. Our overall aim was to understand 
whether BMI is a risk factor for prostate cancer, and to iden-
tify whether failure to account for the role of PSA in many 
prostate cancer diagnoses is likely to lead to biased estimates 
of the association between BMI and prostate cancer.
Methods
Eligibility criteria
We performed a systematic review in which we included 
original articles published in peer reviewed journals that 
measured an association between BMI and total prostate 
cancer incidence and/or advanced prostate cancer; and stud-
ies that measured an association between BMI and PSA, 
including supplements and meeting abstracts; human rand-
omized controlled trials (RCTs), case–control, cohort, cross-
sectional, and non-randomized experimental studies. If the 
abstract did not specifically mention BMI but mentioned 
height or weight, we acquired the full text to determine if 
BMI was calculable from data included in the publication.
We excluded reviews, books, commentaries, letters, and 
animal and cell-line studies; studies examining pre-malig-
nant disease if there was no mention of prostate cancer or 
PSA; studies where BMI was measured after diagnosis of 
prostate cancer, as this increases the likelihood of reverse 
causality; and studies that we considered to be at critical risk 
of bias (see ‘Risk of Bias Assessment’ below).
We determined the effect estimate to be for advanced 
prostate cancer if the individual studies labeled the effect as 
“advanced” or “aggressive,” or if the effect was for locally 
advanced, extra-prostatic, nodular or metastatic prostate 
cancer. Advanced prostate cancer represents clinically 
meaningful cancer, with lower survival rates than non-
advanced cancers. High-grade prostate cancer on its own 
was not considered equivalent to advanced prostate cancer 
and was not extracted, as the definition of “high-grade” has 
been inconsistent over time, incorporating Gleason scores 
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(the definition of which has changed over time [13]), tumor, 
node, metastases [TNM] scores, and PSA levels.
Data sources
We searched Medline and Embase databases up to 02 Octo-
ber 2017 for studies in humans associating BMI with either 
prostate cancer or PSA. The search query was as follows 
(each term as a text word search): (BMI or body mass index 
or obese or obesity or body weight or body size or adipos-
ity) AND (prostate cancer or prostate neoplasm or PSA or 
prostate-specific antigen) NOT psoriatic arthritis. Psoriatic 
arthritis was excluded as its initialism is also PSA. We also 
reviewed the reference lists of previous meta-analyses for 
further studies for inclusion [6, 8, 14]. Duplicate studies 
were removed prior to download using the Ovid deduplica-
tion tool.
Data extraction
One author (SH) screened the titles and abstracts of all 
papers for inclusion and retrieved full texts for all studies 
that met the inclusion criteria. Full texts were also sought 
if no abstract was available or if the abstract did not include 
sufficient information to decide on inclusion. We also sought 
full texts for conference abstracts, if a corresponding full text 
was not found in the original search. If no full text could be 
found, and the abstract provided insufficient information for 
inclusion, the study was excluded. We excluded one pub-
lished paper where we could not locate a full text [15].
One author (SH) screened all full texts for inclusion, and 
one of three independent reviewers (KT, ET, HJ) reviewed 
the first 60 full texts to check for consistency. We resolved 
any inconsistency with discussion to clarify screening crite-
ria. A random subset of the remaining studies [30 full texts] 
was also reviewed by the independent reviewers to check for 
drift from inclusion/exclusion criteria.
Both SH and RL independently extracted all relevant data 
from included studies, with disagreements resolved by dis-
cussion. The first ten extractions were also performed by 
HEJ, KT, and ELT to check for consistency.
We categorized prostate cancer studies as “before” if BMI 
was measured on average at least two years before diagnosis 
(prospective studies), and “same time” if BMI was measured 
on average less than two years before diagnosis. In general, 
“before” studies were cohort studies and “same time” stud-
ies were case–control studies. We considered the “before” 
studies to be at lower risk of reverse causation.
We extracted data that were (or could be transformed to) 
an odds ratio (OR) or hazard ratio (HR) quantifying the con-
tinuous association between BMI and total and advanced 
prostate cancer risk, and a regression coefficient for the 
association between BMI and log-PSA. Log-PSA was used 
as an outcome rather than PSA as we assumed a multiplica-
tive association between BMI and PSA, which fits with the 
theory that haemodilution is responsible for any observed 
association [16]. Studies reported associations in a variety 
of ways; a detailed list of the statistical conversions used to 
estimate the ORs, HRs, and regression coefficients and their 
standard errors (SEs) is in Supplementary appendix 1.
We estimated linear associations, taking BMI as a con-
tinuous exposure variable, and assessing the possibility 
of non-linear associations by coding BMI as a categori-
cal exposure. Specifically, we estimated linear associa-
tions between BMI and the log odds of prostate cancer or 
advanced prostate cancer, and between BMI and log trans-
formed PSA. For simplicity, we refer to linear associations 
as “continuous” throughout. The following BMI categories 
were used: normal weight (BMI < 25 kg/m2), overweight 
(25 kg/m2 ≤ BMI < 30 kg/m2), and obese (BMI ≥ 30 kg/m2). 
We refer to these as “categorical” associations throughout.
When several papers reported on the same study, for con-
tinuous associations we prioritized papers that presented 
continuous effect estimates (e.g., HR or OR per 1 kg/m2 
increase in BMI) over papers presenting categorical effect 
estimates (e.g., HR or OR for overweight and obese groups 
versus normal weight), and these were prioritized over mean 
differences. For categorical associations, we extracted esti-
mates from papers presenting categorical associations only. 
If duplicate studies presented the same effect estimate types 
in multiple papers, the paper with the largest number of 
participants was used in the meta-analysis. If both adjusted 
(e.g., for potential confounders such as age, ethnicity, etc.) 
and unadjusted results were given in the same paper, the 
most-adjusted model was used in the meta-analysis.
If the data were insufficient to estimate a regression coef-
ficient, OR or HR and SE, we extracted a p value, the num-
ber of participants and direction of association from the most 
relevant analysis for use in an albatross plot [17].
Risk of bias assessment
SH and RL assessed the risk of bias in each study inde-
pendently using an assessment tool created for a previous 
meta-analysis [18], with disagreements resolved by discus-
sion. This tool uses the categories of assessment from a draft 
of the ROBINS-I tool [19], and questions from the CASP 
case–control and cohort questionnaires [20, 21], see Sup-
plementary appendix 2.
We assessed risk of bias in six categories: confounding, 
selection of participants, missing data, outcome measure-
ment, exposure measurement, and results’ reporting. We 
assigned overall and category-specific risks of bias: either 
low, moderate, high, critical, or unclear (if there was insuffi-
cient information to assign a risk). We based the overall risk 
of bias on a subjective combination of the category-specific 
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risk of biases, looking at the maximum risk of bias that 
could have been introduced into the study by each category. 
The overall risk of bias was not low in any study, as all 
studies were observational and thus potentially subject to 
unmeasured confounding.
We determined that a study had a critical risk of bias if 
i) age was not accounted for in either the design or analy-
sis of the study and, for BMI-prostate cancer case–control 
studies, if there was more than a 3-year difference in the 
mean or median ages of cases and controls, because age is 
strongly associated with BMI [22], prostate cancer risk [23], 
and PSA [23]; or ii) if the design of the study was such that 
participation was conditional upon PSA levels, both for the 
association between BMI and PSA (as this would involve 
conditioning on the outcome) and the association between 
BMI and prostate cancer (as this would involve conditioning 
on a collider) [24].
Studies with a critical risk of bias were excluded prior to 
analysis and were not considered further.
In the studies found in the systematic review, it was gen-
erally unclear whether men considered as not having prostate 
cancer had received biopsies. Usually, the controls were “not 
known to have prostate cancer,” rather than “known not to 
have prostate cancer.” Therefore, screening could have intro-
duced bias in the association between BMI and prostate can-
cer. Although we did not consider this a critical risk of bias, 
we sought to investigate and quantify this bias using large 
studies where biopsy status was known, and IPD available.
Individual participant data studies
Studies that offered prostate biopsies if the participants’ 
PSA were above threshold values (screening studies) were 
excluded from our systematic review for having a critical 
risk of bias. However, we noted that some of the largest 
potentially relevant studies for our research questions were 
screening studies, and that bias due to screening could 
potentially be accounted for using imputation of prostate 
cancer status if IPD were available. This would then allow 
these studies to be included in the meta-analyses.
We approached four prospective studies looking at pros-
tate cancer to obtain IPD: Krimpen [25], Prostate Cancer 
Prevention Trial (PCPT) [26], Prostate, Lung, Colorectal, 
and Ovarian cancer screening trial (PLCO) [27] and Pros-
tate Testing for cancer and treatment trial (ProtecT) [28]. 
These studies were chosen because they were large studies of 
prostate cancer with known PSA screening protocols, or the 
biopsy status of all participants was known. Key to inform-
ing the imputation model was PCPT, which offered biopsies 
to all participants regardless of PSA level. This information 
allowed us to predict prostate cancer status for men with a 
PSA level below the threshold for biopsy in the other three 
studies using multiple imputation. However, PCPT only 
included men with a PSA less than 3.0 ng/ml, biasing both 
the BMI-PSA and BMI-prostate cancer analyses, and as such 
was excluded from the meta-analyses due to the critical risk 
of bias from conditioning on a collider or outcome. Imputa-
tion is valid if the missing data (prostate cancer status) is 
missing at random given other variables in the imputation 
model, so imputing prostate cancer is not biased even though 
PCPT is restricted to men with a PSA less than 3.0 ng/ml, as 
PSA is in the imputation model [29].
For each IPD study, we requested data measured at 
baseline on BMI and PSA, as well as age, family history 
of prostate cancer and ethnicity. We also requested data on 
prostate cancer status (including tumor, node, metastases 
[TNM], and Gleason scores). For each man who was not 
biopsied, we imputed prostate cancer status by the end of 
the study in which he participated using multiple imputa-
tion. We included baseline age, BMI, log-PSA, family his-
tory of prostate cancer, and study as explanatory variables 
to predict prostate cancer status using multiple imputation. 
BMI, log-PSA, and family history of prostate cancer were 
also imputed if missing.
We checked the validity of the imputation model by 
checking whether the predicted incidence of prostate cancer 
among men without prostate biopsies was credible, given 
results from autopsy studies [30]. Additionally, we visually 
inspected a plot of estimated prostate cancer risk against 
PSA for the imputed studies, to see whether the predicted 
risk of prostate cancer at low PSA levels for each study was 
plausible (see Supplementary Appendix 3.4).
In each of the three included IPD studies, we estimated 
associations between BMI and (1) prostate cancer, (2) 
advanced prostate cancer, and (3) PSA. We restricted the 
analyses to men with white ethnicity (due to low numbers 
of non-white men and therefore difficulties in imputation), 
and adjusted the analyses for age, family history of prostate 
cancer (for prostate cancer analyses), and prostate cancer 
status (for the PSA analyses). Full details of the IPD studies, 
the imputation method, and statistical analyses are available 
in Supplementary Appendix 3.
Combining data
Meta‑analysis
We combined estimates from studies identified through the 
systematic review and the IPD studies using random-effects 
and fixed-effect meta-analyses. We performed separate meta-
analyses of continuous and categorical associations for each 
outcome (prostate cancer, advanced prostate cancer, and 
PSA). All meta-analysis results are presented in forest plots.
Studies presenting HRs and ORs were analyzed and pre-
sented separately. For studies presenting ORs, “same time” 
and “before” studies were meta-analyzed in subgroups, 
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and labeled as such in forest plots. Studies presenting HRs 
were all classed as “before” studies, and labeled simply 
“HR.” The results are presented as the HR or OR for pros-
tate cancer or advanced prostate cancer and percentage 
change in PSA for a 5 kg/m2 increase in BMI. Heterogene-
ity was tested for and quantified using the Cochran’s Q and 
 I2 statistics [31, 32].
In meta-analyses of categorical associations, studies 
from the systematic review were included if they presented 
ORs or HRs for overweight and/or obese men relative to 
normal weight men (for the outcomes of prostate cancer 
and advanced prostate cancer) or means and SDs of PSA 
or log-PSA for each of these BMI categories (for the out-
come of PSA). ORs and HRs that were presented for other 
categories of BMI were not used (such as morbidly obese, 
BMI ≥ 35 kg/m2), though we combined the mean and SD 
of PSA for different categories with neighboring catego-
ries when sufficient information was available.
Meta‑regression
Meta-regression [33] was used to determine if the effect 
estimates from individual studies included in the meta-
analyses varied by study-level factors. For all meta-regres-
sions, we considered ethnicity (non-white versus white in 
each study, defined as > 80% white participants or from a 
country with a majority white population), mid-year of 
recruitment, mean BMI in the study, and the overall risk of 
bias (high versus medium). For the associations between 
BMI and prostate cancer and advanced prostate cancer, we 
also considered the mean age at diagnosis, and study mean 
time between BMI measurement and diagnosis.
Funnel plots
Funnel plots [34] were drawn to assess for small study 
effects in each analysis [35].
Albatross plots
As not all studies reported enough information to be 
included in the meta-analyses, we also present albatross 
plots containing results from studies with and without suf-
ficient information to be included in the meta-analyses [17]. 
These are plots of the p value of an association against the 
number of participants and can be used to assess heteroge-
neity between studies and assess the rough magnitude of an 
association using limited information. By indicating which 
studies had insufficient data to contribute to meta-analysis on 
the albatross plots, we determined whether inclusion of the 
remaining studies would have altered the overall interpreta-
tion of the evidence.
Results
In total, 9,127 papers were found that had keywords for 
BMI and prostate cancer or PSA. After title and abstract 
screening, 725 papers remained (see Fig. 1, PRISMA flow 
diagram). After full text screening, risk of bias assessment, 
and removal of papers reporting the same studies, 78 stud-
ies examined the association between BMI and prostate 
cancer [67 with data for meta-analysis], 21 studies exam-
ined the association between BMI and advanced prostate 
cancer [18 with data for meta-analysis], and 35 studies 
examined the association between BMI and PSA [20 with 
data for meta-analysis, one of which only had data for 
categorical associations].
A summary of all results is given in Table 1.
BMI and prostate cancer
Continuous BMI
Of the 78 studies examining the association between BMI 
and prostate cancer [25, 27, 28, 36–110], 11 (14%) could 
not be included in the meta-analysis due to insufficient 
data but were included in the albatross plot [100–110]. 
All studies are detailed in Supplementary Table 1, with 
the results of the risk of bias assessment in Supplementary 
Table 2. All studies in the meta-analysis adjusted for age 
in either the study design or analysis, while 23 studies 
(34%) adjusted for smoking status, 22 (33%) for ethnicity, 
20 (30%) for family history of prostate cancer, 13 (19%) 
for education, 10 (15%) for area, 10 (15%) for diabetes, 
10 (15%) for physical activity, 9 (13%) for alcohol, 6 (9%) 
for diet, and 6 (9%) for income. No other variable (of 24 
other variables) was adjusted for in more than four studies.
In total, 9,513,326 men from 67 studies were included 
in the HR and OR meta-analyses, (9,351,795 in 30 HR 
studies, 161,531,383 in 37 OR studies); of these, 201,311 
(2.1%) men had prostate cancer (157,990 cases [1.7%] in 
HR studies, 41,863 [25.9%] in OR studies). The random-
effects meta-analyses (Figs. 2 and 3) estimated the average 
HR and OR for prostate cancer for a 5 kg/m2 increase in 
BMI to be 1.01 (95% CI 0.99–1.04, p = 0.29) and 0.99 
(95% CI 0.96–1.02, p = 0.64), respectively. There was 
strong evidence for heterogeneity in effect estimates 
across studies for the studies reporting an HR (p < 0.001, 
 I2 = 79.9%), and studies reporting an OR (p < 0.001, 
 I2 = 65.8%). Pooled estimates from fixed-effect meta-
analyses were essentially the same. 
 Cancer Causes & Control
1 3
From a meta-analysis including only IPD studies, the 
estimated average OR for prostate cancer for a 5 kg/m2 
increase in BMI was 0.98 (95% CI 0.95–1.01) (Supple-
mentary Appendix 3.6). Analyzed without imputation 
(complete case analysis), the estimated OR was only 0.94 
(95% CI 0.91–0.97).
There was limited evidence of (positive) small study 
effects on the funnel plot for HRs, but not ORs (Supple-
mentary Figs. 1 and 2). The albatross plot (Supplementary 
Fig. 3) showed that the eleven studies without sufficient 
information for meta-analysis were spread evenly across 
both positive and negative effect sizes, consistent with the 
null result seen in the meta-analysis.
Fig. 1  PRISMA flow diagram showing the number of studies in each stage of the systematic review
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Meta-regression (Supplementary Table 3) on study-
level variables did not explain any of the heterogeneity.
Categorical BMI
Thirteen of the studies included in the continuous meta-
analyses above presented HRs or ORs for overweight and/
or obese men versus normal weight men [25, 27, 28, 45, 52, 
53, 60, 69–72, 78, 111]. Only ten studies presented HRs 
or ORs for overweight men, whereas all thirteen presented 
HRs or ORs for obese men versus normal weight men. In 
total, there were 252,771 participants and 32,277 men with 
prostate cancer included in this meta-analysis; two studies 
[53, 111] did not report how many men were in each BMI 
subgroup and were not included in these totals.
Supplementary Table 4 shows the mean BMI, total num-
ber of men, and number of men with prostate cancer in each 
category of BMI, and Supplementary Table 5 shows the HRs 
and ORs for prostate cancer for each study for overweight 
and obese versus normal weight men. Forest plots are pre-
sented in Supplementary Figs. 4 and 5. For the random-
effects meta-analysis, the average HR for prostate cancer 
between overweight and normal weight men was estimated 
to be 1.02 (95% CI 0.98–1.05, p = 0.35) with no evidence of 
heterogeneity  (I2 = 0.0%, p = 0.66), and the average OR was 
estimated to be 0.99 (95% CI 0.91–1.08, p = 0.81, combined 
across ORs for BMI measured before and at the same time 
as prostate cancer diagnosis) with little evidence of hetero-
geneity  (I2 = 32.6%, p = 0.19). The average HR for prostate 
cancer between obese and normal weight men was estimated 
to be 0.97 (95% CI 0.93–1.01, p = 0.16), with no evidence 
of heterogeneity  (I2 = 0.0%, p = 0.80), and the average OR 
was estimated to be 0.90 (95% CI 0.81–1.00, p = 0.05, com-
bined across ORs), with some evidence of heterogeneity 
 (I2 = 41.6%, p = 0.10). Fixed-effect models gave very simi-
lar results.
The heterogeneity in the average OR for prostate can-
cer between obese and normal weight men may have been 
due to differences between IPD and non-IPD studies. There 
was no evidence of heterogeneity for either IPD (OR = 0.97, 
95% CI 0.91–1.04, p = 0.46) or non-IPD (OR = 0.77, 95% 
CI 0.67–0.89, p < 0.001) studies when considered separately 
 (I2 = 0.0% for both, p = 0.93 and p = 0.54, respectively).
Table 1  Summary of results
Linear models used random-effects meta-analysis, estimating the average effect across all studies for a 5 kg/m2 increase in BMI. Categorical 
models used random-effects meta-analysis, estimating the average effect across all studies
Prostate Cancer
 • Continuous:
    ○ HR = 1.01 (95% CI 0.99–1.04, p = 0.29)
    ○ OR = 0.99 (95% CI 0.96–1.02, p = 0.64)
 • Categorical: Overweight versus normal weight:
    ○ HR = 1.02 (95% CI 0.98–1.05, p = 0.35)
    ○ OR = 0.99 (95% CI 0.91–1.08, p = 0.81)
 • Categorical: Obese versus normal weight:
    ○ HR = 0.97 (95% CI 0.93–1.01, p = 0.16)
    ○ OR = 0.90 (95% CI 0.81–1.00, p = 0.05)
Advanced Prostate Cancer
 • Continuous:
    ○ HR = 1.06 (95% CI 1.01–1.12, p = 0.013)
    ○ OR = 1.00 (95% CI 0.94–1.06, p = 0.99)
 • Categorical: Overweight versus normal weight:
    ○ HR = 1.04 (95% CI 0.94–1.15, p = 0.44)
    ○ OR = 1.09 (95% CI 0.91–1.29, p = 0.35)
 • Categorical: Obese versus normal weight:
    ○ HR = 1.15 (95% CI 0.92 to 1.44, p = 0.22)
    ○ OR = 1.00 (95% CI 0.82–1.23, p = 0.97)
PSA
 • Continuous:
    ○ Percentage change = − 5.88% (95% CI − 6.87 to − 4.87, p < 0.001)
 • Categorical: Overweight versus normal weight:
    ○ Percentage change = − 3.43% (95% CI − 5.57 to − 1.23, p = 0.002)
 • Categorical: Obese versus normal weight:
    ○ Percentage change = − 12.9% (95% CI − 15.2 to − 10.7, p < 0.001)
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BMI and Advanced Prostate Cancer
Continuous BMI
Of the 21 studies examining the association between BMI 
and advanced prostate cancer [25, 27, 28, 40, 42, 49, 52–55, 
57, 58, 65, 93, 98, 103, 104, 107, 112–114], 3 studies (14%) 
could not be included in the meta-analysis due to insuffi-
cient data but were included in an albatross plot [103, 104, 
107]. The studies examining the association between BMI 
and advanced prostate cancer are detailed in Supplemen-
tary Table 6, with the results of the risk of bias assessment 
in Supplementary Table 7. All studies in the meta-analysis 
adjusted for age in either the study design or analysis, while 
9 studies (50%) adjusted for smoking status, 9 (50%) for 
family history of prostate cancer, 8 (44%) for ethnicity, 7 
(39%) for education, 6 (33%) for diabetes, and 5 (28%) for 
physical activity. No other variable (of 15 other variables) 
was adjusted for in more than four studies.
In total, 1,146,847 men were included from 18 studies 
(1,052,344 in 11 HR studies, 94,503 in seven OR studies); 
of these, 12,037 (1.0%) men had advanced prostate cancer 
(8,123 [0.8%] in HR studies, 3,914 [4.1%] in OR stud-
ies). The random-effects meta-analyses (Fig. 4 and Fig. 5) 
estimated the average HR and OR for advanced prostate 
cancer for a 5 kg/m2 increase in BMI to be 1.06 (95% CI 
1.01–1.12, p = 0.013) and 1.00 (95% CI 0.94–1.06, p = 0.99), 
respectively. There was little evidence for heterogeneity in 
effect estimates across studies reporting an HR  (I2 = 24.4%, 
p = 0.21), and no evidence for heterogeneity in effect esti-
mates across studies reporting an OR  (I2 = 0.0%, p = 0.54). 
The fixed-effect analysis showed essentially the same results.
Fig. 2  Forest plot for the association between BMI and prostate cancer (hazard ratios)
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When IPD studies were analyzed separately, the estimated 
average OR for advanced prostate cancer for a 5 kg/m2 
increase in BMI was 1.00 (95% CI 0.92–1.09), Supplemen-
tary Appendix 3.6. The effect estimate when analyzed with-
out imputation (complete case analysis) was slightly lower, 
with an estimated average OR of 0.98 (95% CI 0.89–1.08).
The funnel plots (Supplementary Figs. 6 and 7) did 
not show evidence of any small study effects. The alba-
tross plot (Supplementary Fig. 8) showed that the three 
studies without sufficient information for meta-analysis 
all estimated a positive association between BMI and 
advanced prostate cancer risk. One small study of 1,474 
men, Putnam (2000) [104], estimated an inconsistently 
strong effect. Because this study was so small, it does not 
change our interpretation of the meta-analyses.
Meta-regression (Supplementary Table 8) did not show 
evidence of any variation in results due to study-level 
variables.
Fig. 3  Forest plot for the association between BMI and prostate cancer (odds ratios)
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Categorical BMI
Six of the studies included in the continuous meta-analysis 
presented HRs or ORs for overweight and/or obese men 
versus normal weight men [25, 27, 28, 52–54]. Only five 
studies presented results for overweight versus normal 
weight men, whereas all six presented results for obese 
versus normal weight men. In total, there were 169,530 
participants included in this analysis, and 2,381 men had 
advanced prostate cancer (1.4%) (one study [53] did not 
report how many men were in each BMI subgroup and was 
not included in these totals).
Supplementary Table 9 shows the mean BMI, total 
number of men, and number of men with advanced pros-
tate cancer in each category of BMI, and Supplementary 
Table 10 shows the HRs and ORs for advanced prostate 
cancer, for each study for overweight and obese versus 
normal weight men. Forest plots are presented in Supple-
mentary Figs. 9 and 10. For the random-effects meta-anal-
ysis, the average HR for advanced prostate cancer between 
overweight and normal weight men was estimated to be 
1.04 (95% CI 0.94–1.15, p = 0.44), with no evidence of 
heterogeneity  (I2 = 0.0%, p = 0.74), and the average OR 
was estimated to be 1.09 (95% CI 0.91–1.29, p = 0.35), 
with no evidence of heterogeneity  (I2 = 0.0%, p = 0.78). 
The average HR for advanced prostate cancer between 
obese and normal weight men was estimated to be 1.15 
(95% CI 0.92–1.44, p = 0.22), with evidence of hetero-
geneity  (I2 = 53.7%, p = 0.02), and the average OR was 
estimated to be 1.00 (95% CI 0.82–1.23, p = 0.97), with 
no evidence of heterogeneity  (I2 = 0.0%, p = 0.74). Fixed-
effect models gave very similar results.
BMI and PSA
Continuous BMI
Of the 34 studies providing information on the association 
between BMI (as a continuous variable) and PSA [25, 27, 
28, 115–145], 15 studies (42%) could not be included in the 
meta-analysis due to insufficient data but were included in 
an albatross plot [131–145]. All included studies are detailed 
Fig. 4  Forest plot for the association between BMI and advanced prostate cancer (hazard ratios)
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in Supplementary Table 11, with the results of the risk of 
bias assessment in Supplementary Table 12. All studies in 
the meta-analysis adjusted for age in either the study design 
or analysis, while 9 studies (47%) adjusted for ethnicity. No 
other variable (of 13 other variables) was adjusted for in 
more than four studies.
In total, 264,970 men from 19 studies were included in 
the meta-analysis. The random-effects meta-analysis (Fig. 6) 
estimated the average percentage change in PSA for a 5 kg/
m2 increase in BMI to be -5.88% (95% CI − 6.87 to − 4.87, 
p < 0.001). There was strong evidence for heterogeneity in 
effect estimates across studies  (I2 = 60.0%, p < 0.001). The 
fixed-effect analysis showed essentially the same result 
with narrower confidence intervals (percentage change in 
PSA = -− 5.99%, 95% CI − 6.48 to − 5.49, p < 0.001).
The funnel plot (Supplementary Fig. 11) showed little 
evidence of small study effects. The albatross plot (Sup-
plementary Fig. 12) showed that the excluded studies were 
broadly consistent with the meta-analysis effect size.
Meta-regression (Supplementary Table  13) did not 
explain any of the observed heterogeneity.
Categorical BMI
Sixteen of the studies included in the continuous meta-anal-
ysis presented PSA or log-PSA levels for overweight and/
or obese men and normal weight men [25, 27, 28, 115–122, 
124, 125, 127, 129, 146], and one further study presented 
only categorical results [147]. Overall, there were 17 studies 
and 218,700 participants included in this analysis.
Supplementary Table 14 displays the average log-PSA 
in each BMI subgroup for all 17 included studies, and 
Supplementary Table  15 displays the percentage MD 
in PSA for all comparisons. Forest plots are presented 
in Supplementary Figs.  13 and 14. For the random-
effects meta-analysis, the average percentage change in 
PSA between overweight and normal weight men was 
estimated to be −  3.43% (95% CI −  5.57 to −  1.23, 
Fig. 5  Forest plot for the association between BMI and advanced prostate cancer (odds ratios)
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p = 0.002), with strong evidence of heterogeneity across 
studies  (I2 = 80.9%, p < 0.001), and the average percent-
age change in PSA between obese and normal weight 
men was estimated to be − 12.9% (95% CI − 15.2 to 
− 10.7, p < 0.001), with strong evidence of heterogene-
ity across studies  (I2 = 69.5%, p < 0.001). The pooled 
estimates from fixed-effect meta-analyses were slightly 
lower for the change in PSA between overweight and 
normal weight men (percentage change = -2.56%, 95% CI 
− 3.34 to − 1.78, p < 0.001), but similar for the change in 
PSA between obese and normal weight men (percentage 
change = -12.1%, 95% CI − 13.2 to − 11.1, p < 0.001).
The difference in log-PSA between the obese and 
normal groups (-0.139) was almost four times the differ-
ence between the overweight and normal weight groups 
(-0.035). The weighted mean BMI across all studies was 
22.2 kg/m2 for the normal BMI category, 26.5 kg/m2 for 
the overweight category, and 31.3 kg/m2 for the obese 
category. We therefore consider this evidence that there 
is a non-linear association between BMI and log-PSA.
Fig. 6  Forest plot for the association between BMI and PSA. AD aggregate data from systematic review, IPD individual participant data
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Discussion
Overall prostate cancer
There was no compelling evidence to suggest there is a 
linear association between BMI and prostate cancer risk 
as the effect estimate was null with a very tight confidence 
interval, nor an association between being overweight and 
prostate cancer risk, and only weak evidence for a small 
reduction in prostate cancer risk in obesity. However, there 
is likely a reduced risk of being diagnosed with prostate 
cancer in overweight/obese men due to the role of PSA 
screening or testing in many prostate cancer diagnoses. 
This is reflected in our analyses of the IPD studies: the 
complete case analysis in which we ignored the problem 
of incomplete diagnosis (not all men being biopsied) sug-
gested a negative association between BMI and prostate 
cancer. This association was attenuated to the null after 
imputation of missing prostate cancer status in non-biop-
sied men. This finding is consistent with our hypothesis 
regarding the expected direction of bias due to the negative 
association of BMI with PSA.
Obese men with prostate cancer may also have a higher 
risk of missed diagnoses due to having larger prostates 
[148], which are associated with a lower likelihood of 
detecting prostate cancer at biopsy [149, 150]. Bias from 
PSA testing will be highest in populations with a high level 
of PSA screening. In other populations, obesity may affect 
the chance of receiving a PSA test, and therefore receiving a 
prostate cancer diagnosis, for example, if obese men access 
primary care more.
Overall, our results are consistent with previous meta-
analyses. A random-effects dose–response meta-analysis of 
prospective studies was conducted by Markozannes et al. [4] 
using data from the World Cancer Research Fund (WCRF) 
as part of the continuous update project [151]. Markozannes 
included 39 studies with 3,798,746 participants and 88,632 
men with prostate cancer (2.3%) for the association between 
BMI and prostate cancer (excluding studies on mortality), 
including many of the same studies we included in our meta-
analysis. The pooled risk ratio (RR) for prostate cancer for 
a 5 kg/m2 increase in BMI was 1.00 (95% CI 0.97–1.03), 
consistent with our results. In addition, an umbrella review 
of systematic reviews and meta-analysis by Kyrgiou et al. [3] 
concluded that there was no strong evidence for an associa-
tion between BMI and prostate cancer risk, with a summary 
OR for prostate cancer for a 5 kg/m2 increase in BMI of 1.03 
(95% CI 0.99–1.06).
Advanced prostate cancer
There was some evidence to suggest a positive linear asso-
ciation between BMI and the risk of advanced prostate can-
cer, but only among studies reporting an HR (HR = 1.06, 
95% CI 1.01–1.12, p = 0.013). This association was null in 
studies reporting an OR (OR = 1.00, 95% CI 0.94–1.06), but 
still consistent with a small positive association in studies, 
such that the difference between the two groups of stud-
ies may be due to chance or differences in study design or 
population. Additionally, there may be collider bias [24] in 
both estimates from conditioning on prostate cancer, since 
any unmeasured confounders associated with both prostate 
cancer and advanced prostate cancer could induce an asso-
ciation between BMI and advanced prostate cancer.
Markozannes conducted a meta-analysis of prospective 
studies of BMI and combined advanced, high-grade, and 
fatal prostate cancer using WCRF data, which included 23 
studies with 1,676,220 participants and 11,204 men with 
advanced/high-grade/fatal prostate cancer (0.67%) [4]. 
The RR for advanced/high-grade/fatal prostate cancer for 
a 5 kg/m2 increase in BMI was 1.08 (95% CI 1.04–1.12). 
The effect estimate may be increased in the WCRF analysis 
by the inclusion of high-grade and/or fatal prostate cancers 
or exclusion of case–control studies. Kyrgiou et al. [3] con-
cluded that there was weak evidence for a positive associa-
tion between increasing BMI and advanced prostate cancer 
risk, with a RR for advanced prostate cancer for a 5 kg/
m2 increase in BMI of 1.09 (95% CI 1.02–1.16), although 
our meta-analysis included more up-to-date studies with a 
stricter inclusion criteria.
PSA
There was strong evidence of an inverse association between 
BMI and PSA, which we found to be likely non-linear, 
decreasing more quickly between overweight and obese 
than normal weight and overweight. On average, obese men 
have an estimated 12.9% lower PSA than a normal weight 
man, and overweight men 3.4% lower PSA. We could only 
find one previous review of the association between BMI 
and PSA, which did not include a meta-analysis or estimate 
effect size [152]. Their conclusion was that many studies 
reported an inverse association between BMI and PSA, in 
agreement with our findings.
It could thus be potentially beneficial to account for BMI 
when interpreting the results of a PSA test, however, pro-
spective research would be necessary to confirm whether 
this would have a beneficial effect on prostate cancer-
related outcomes. One suggestion based on these results is 
to increase an overweight man’s PSA by 3.5% (multiply by 
1.035) before comparing to a threshold, and an obese man’s 
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PSA by 13% [10, 153]. As an example of the impact of doing 
so, 23% of men in ProtecT were obese, and 1.9% of these 
men had an observed PSA of less than 3.0 ng/ml, but a ‘cor-
rected’ PSA above a 3.0 ng/ml threshold for biopsy when 
adjusted for the effect of BMI on PSA.
Strengths and Limitations
We synthesized data from many studies, including par-
ticipants from many different populations at different time 
points, improving generalizability. The total number of par-
ticipants included in analyses was also very large, and as 
such all pooled effect estimates were precise. By including 
studies where BMI was measured before, and those where it 
was measured at the same time as prostate cancer detection, 
we could compare different study types: there was little dif-
ference between these two study types for all outcomes in 
the continuous analyses, suggesting the findings are robust to 
reverse causation of BMI change by prostate cancer diagno-
sis. By including IPD studies and imputing prostate cancer 
status in men who were not biopsied, we were able to show 
and account for bias in the association between BMI and 
prostate cancer from PSA testing.
A further strength of this study was the inclusion of stud-
ies where only a p value and number of participants could 
be extracted, using albatross plots.
However, there are limitations. Many of the studies 
included in the meta-analysis compared men with a diag-
nosis of prostate cancer versus men without a diagnosis of 
prostate cancer. In the screening studies, most men were 
not biopsied. Assuming that none of these men had prostate 
cancer would be a strong assumption and likely lead to bias. 
We addressed this problem by treating prostate cancer status 
as missing in these men and using multiple imputation. We 
performed checks on the validity of our imputation model, 
but we note the limitation that our results may have been 
sensitive to the choice of this model. In the meta-analysis of 
all studies, we limited bias due to testing for prostate can-
cer with PSA by excluding studies that exclusively screened 
for prostate cancer (and thus would have the greatest bias), 
but as PSA screening is used in general practice the bias 
could not be entirely removed. The proportion of prostate 
cancers detected by testing with PSA likely varied in each 
study, potentially accounting for some of the heterogene-
ity in studies examining the association between BMI and 
prostate cancer and advanced prostate cancer. Indeed, all 
the heterogeneity between OR results for prostate cancer 
between obese and normal weight men were due to differ-
ences between the imputed IPD studies versus the non-IPD 
studies.
Overall, there were large amounts of heterogeneity 
between non-IPD studies in the continuous analyses of 
BMI and prostate cancer, and advanced prostate cancer. This 
could be due to heterogeneity across populations, methods 
of diagnosing prostate cancer, or differential adjustment 
for confounders in each study-specific analysis. Equally, 
because the studies may not have used the same definition 
of advanced prostate cancer, and because advanced prostate 
cancers could be locally advanced prostate cancer, nodes or 
metastatic cancer, these studies may be relatively heteroge-
neous. This may have attenuated any association between 
BMI and advanced prostate cancer. Additionally, PSA test-
ing rates changed differently over time in different countries, 
and although we tested for an effect of changing PSA testing 
rates over time using meta-regression, we may not have been 
able to capture differences in effect estimates for prostate 
cancer between studies from changing PSA testing rates, as 
well as differences between countries.
There was also evidence of heterogeneity between stud-
ies examining the associations between BMI and PSA. As 
with the prostate cancer studies, the PSA studies adjusted for 
different confounders, therefore residual confounding may 
have increased heterogeneity. It is also possible the associa-
tion between BMI and PSA varies by population, though 
our meta-regressions did not find any explanatory factors.
There was at least a moderate risk of bias for all studies, 
as all studies were observational and therefore could have 
been biased by unobserved confounding. We attempted to 
limit effects of bias by identifying key confounders and only 
including studies without a critical risk of bias. There was 
also no evidence from the meta-regression that the studies 
with a medium risk of bias had systematically different effect 
estimates than those with a high risk of bias.
In the categorical analyses, it was only possible to 
combine studies presenting results for specific categories 
of BMI. As such, relatively few studies were included; a 
superior approach would be to gather IPD from all eligible 
studies and to determine the precise form of any non-linear 
associations, which would also allow more accurate correc-
tions to men’s PSA levels.
Conclusion
There was little evidence of any association between BMI 
and prostate cancer risk, and some evidence for a small posi-
tive association with advanced prostate cancer risk. There 
was, however, strong evidence for an inverse non-linear 
association between BMI and PSA. There was evidence 
from IPD studies to suggest this could bias the association 
between BMI and prostate cancer in screening studies. Stud-
ies in populations where PSA testing is involved in diagno-
sis of prostate cancer should determine whether an expo-
sure could be associated with PSA, and thus whether the 
observed association with prostate cancer could be biased.
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